Clinical Trial Update: Afrezza® INHALE-1 Study in Pediatrics [Phase 3]

View source ↗

Summary

Afrezza INHALE-1, a pediatric Phase 3 trial of inhaled insulin, has been completed. The study evaluated Afrezza in children with Type 1 and Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED